But I'm personally disappointed with management performance over the past few months.
Im sure many investors, myself included, were eagerly awaiting the previously promised GBM trial results update this year. Only to learn from the latest non-price sensitive investor presentation that the trial has been halted pending a redesign.
No official announcement to the market.
Pretty poor form from management IMO.
Further GBM results are now at least another year away, possibly two. Sure, that might make CHM 1101 a more commercially viable product in the long run. Meanwhile there is very little on the horizon for a possible MC rerate, which we desperately need in order to raise any meaningful cash.
I do wonder whether we'll see any meaningful CDH17 data this year, other than dose escalation and preliminary saftey.
CHM Price at posting:
1.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)